Latest News Archive

Please select Category, Year, and then Month to display items

Voices from the Free State podcast: Episode five – featuring Dr Anchen Laubscher

07 June 2021 | Story Dr Nitha Ramnath

A passion for evidence-based medicine and the notion of value in healthcare is what drives Dr Anchen Laubscher, our guest in the fifth episode of the Voices from the Free State podcast. Anchen is driven to ensure that healthcare is scientifically proven, of high quality, cost effective, and tailored to a patient’s needs.

François van Schalkwyk and Keenan Carelse, UFS alumni leading the university’s United Kingdom Alumni Chapter, have put their voices together to produce and direct the podcast series. Intended to reconnect alumni with the university and their university experience, the podcasts will be featured on the first Monday of every month, ending in November 2021. Our featured alumni share and reflect on their experiences at the UFS, how it has shaped their lives, and relate why their ongoing association with the UFS is still relevant and important. The podcasts are authentic conversations – they provide an opportunity for the university to understand and learn about the experiences of its alumni and to celebrate the diversity and touchpoints that unite them.

Our podcast guest

Anchen joined Netcare in 2007 as an aeromedical doctor and has been with the group for almost 14 years. As Group Medical Director of Netcare Ltd, Anchen is responsible for the strategic oversight and operational execution of all clinical and quality-related matters across the different divisions of Netcare. Leading a team of subject matter experts, Anchen oversees the group’s key deliverables related to the value of care, encompassing quality outcomes, patient safety, patient experience, and episode cost efficiency, with all components of ‘value’ digitally enabled and data driven.

Anchen is a member of the Hospital Association of South Africa (HASA) subcommittee for Clinical Quality and the South African Committee of Medical Deans (SACOMD) initiative, which was constituted to address the human resource dilemma specifically related to the training of doctors in South Africa. She is a Council member of the University of the Free State, where she also serves on the Senate and holds director appointments in the Mother and Child Academic Hospital (MACAH) Foundation, the My Walk My Soul collaboration between Netcare and Adcock-Ingram and the University of Cape Town Medical Centre Ltd. Anchen played a pioneering leadership role in South Africa’s response to the 2014 global Ebola Virus Disease (EVD) outbreak, which continues in her role as Gold Command in Netcare and as member of various national committee and advisory structures related to the COVID-19 pandemic preparedness and response. For her role in the South African EVD response, she was recognised with an honorary award from the South African Military Health Services (SAMHS).

Clinically, Anchen continues to contribute to the specialty of emergency medicine, specifically pre-hospital and aeromedicine. She continues to be involved at her alma mater through ad hoc lecturing in electives, research support at GIBS, and participating in health-care courses and conferences such as the 2020 Healthcare Industry Update and Innovation Conference.

Stay tuned for episode six to be released on 5 July 2021.

For further information regarding the podcast series, or to propose other alumni guests, please email us at alumnipodcast@ufs.ac.za

Listen to all the Voices from the Free State podcasts.

News Archive

Nuclear Medicine on the forefront of cancer research

2017-07-10

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma. The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

Back

Economic and Management Sciences

Education

Health Sciences

The Humanities

Law

Natural and Agricultural Sciences

Theology and Religion

Open Distance Learning

Business School

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept